Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) - Test2 - elhamkhani - TriplyDB

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

http://www.wikidata.org/entity/Q28193306

about

sameAs

Hormone therapy for preventing cardiovascular disease in post-menopausal women Hormone therapy for preventing cardiovascular disease in post-menopausal women Steroid sex hormones for lower limb atherosclerosis Long term hormone therapy for perimenopausal and postmenopausal women Hormone replacement therapy for women previously treated for endometrial cancer Hormone therapy in women with premature ovarian failure Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Hormone replacement therapy for women previously treated for endometrial cancer Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?A review of the relationships between endogenous sex steroids and incident ischemic stroke and coronary heart disease events Role of estrogen in diastolic dysfunction Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases Sex differences in the pathophysiology, treatment, and outcomes in IHD Drug therapy for prevention of recurrent myocardial infarction Estrogen, aging and the cardiovascular system Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression Sex differences in cardiovascular disease - Impact on care and outcomes.Long-term hormone therapy for perimenopausal and postmenopausal women.New evidence for cardiac benefit of postmenopausal hormone therapy.Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women.Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps.Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women.Hormone replacement therapy and secondary cardiovascular prevention: a meta-analysis of randomized trials.The effect of TCM acupuncture on hot flushes among menopausal women (ACUFLASH) study: a study protocol of an ongoing multi-centre randomised controlled clinical trial.Estradiol stimulates vasodilatory and metabolic pathways in cultured human endothelial cells.Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease.Forecasting drug utilization and expenditure in a metropolitan health region.Estradiol-17beta stimulates specific receptor and endogenous nitric oxide-dependent dynamic endothelial protein S-nitrosylation: analysis of endothelial nitrosyl-proteome.Cardiovascular diseases in American women.Gender dimorphisms in progenitor and stem cell function in cardiovascular disease.Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women.Message about hormone replacement therapy is unclear.Making decisions about hormone replacement therapy Lessons from the Women's Health Initiative: primary prevention and gender health.Steroid sex hormones for lower limb atherosclerosis.The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women

P2860

Q24187326-FE888C65-FB1D-405C-A54D-5728F1AFE51A Q24197712-FB13324D-56D7-4CCE-B87C-F072A4D46631 Q24198081-2624D2C3-ADF1-4E11-8E91-0004949061B8 Q24201974-0E3A28D0-B2BD-4B6A-A676-04A95FB3A9F0 Q24234201-F0CB89A0-9C05-49B5-93B4-FDB9E31C22E0 Q24239825-9FA7145E-C846-4CCF-B5FA-EC3CFDF5576E Q24244146-2AC28659-1FA2-4FF0-907B-A727B0B0E719 Q24629580-34770B64-4439-41EF-B208-7440959260DA Q24658109-8231CEC5-38B4-4C87-A839-E9A2C771A09C Q26471218-E35E2C47-29ED-4028-B63B-14A14B40FFED Q26740253-AC3CFEB9-CFF0-43DE-9F5F-60DBA7E1945E Q26822460-6502F510-8242-4864-8D0A-8218447753F4 Q27026798-329DC856-1543-456B-B0CF-9D4893ADEAFB Q28069213-42809DD7-4D03-4F5B-8195-733D554828FC Q28084204-342ED2D0-46A6-4540-BDEE-D43435CDE6A4 Q28165520-D430ABE7-3CE9-44DB-91C4-8D2849240854 Q28383144-25845AEA-FF29-44A5-9DE5-FF218B809B3A Q28569728-49227D78-1B8C-4495-B3CA-C42D650A795D Q28576245-C3E92FA7-C6F7-4260-88DE-13CCC182EB08 Q30234726-50F4122E-9B14-44E5-9E1F-E68321829B62 Q30238978-64AE0E54-CEB3-4625-BB56-4365583A1687 Q30396979-696D165D-597D-4027-AD0F-A822C6083F91 Q30838964-62625878-D792-491C-B422-7F49DBC561C5 Q30841046-019216F0-754C-4AC0-953B-48EE8CFE7C6F Q31030851-B0AC0F79-7E3F-4B85-B6EB-00DDDF3CBB5A Q33222171-E7A44743-C209-492B-A836-741515DEA639 Q33275591-C156B3F2-37D2-4361-A77A-13BD195B5203 Q33518553-1A38AE9E-C557-4AD5-BB71-D1CB117FD4F9 Q33572292-587E494F-976B-453F-B8E2-BF7FBDEA607B Q33579584-B2372AAE-26B2-43D2-BC91-159CA7280698 Q33592650-AEA7ED8D-0B90-4785-932B-704B478D5DE3 Q33689317-2CA64CB4-27F0-4A3A-A1B2-007EDF437C0F Q33771819-DCA95085-B8B2-4C6D-B60B-D71769051409 Q33781367-5D732217-4ECA-4084-9703-245988E2CDF3 Q33797836-F22D1EF2-D42A-47CE-94FD-CFFDD870D2C3 Q33812689-6678E76E-2A29-42FE-8956-554A3498D441 Q33813785-A02E8F90-3E3E-4621-BE0E-3D9AEA183E5C Q33902197-AAE52148-52E2-479E-8BEE-B4AA8AF7DF19 Q33908587-43DF9AAA-9EAA-4CB1-B3BA-CEA529C11612 Q33917513-7ED54E96-211E-47C7-9E27-83EEB231EA8A

P2860

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

http://www.wikidata.org/entity/Q28193306

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@ast

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@en

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@nl

type

label

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@ast

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@en

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@nl

prefLabel

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@ast

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@en

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@nl

P1433

Q28193306-A2B00CAA-DED6-49FA-8C77-C45730B0E754

P1476

Q28193306-93A46D22-34E1-4786-8D56-C6E346B060E8

P2093

Q28193306-3B1787D1-4FAE-42AA-AEB6-494F749D19BD

Q28193306-4554D6AE-ED82-4143-9E8F-E434A29EB27E

Q28193306-4F8BD127-4CD3-4B78-8226-0D18DAAF4BFF

Q28193306-53823756-876D-4B40-B4B2-8243ADF80565

Q28193306-62E90062-FC28-48FC-BC17-998AE8B7FB38

Q28193306-63F2D5AB-D808-4743-B535-82A91BD6AB6F

Q28193306-702D2C71-46F5-46C9-8F55-5A504B1832A4

Q28193306-7995B21D-5C75-49D3-9F32-334098C90D1C

Q28193306-948F31B7-8FE4-418E-B890-7B0313DA0005

Q28193306-9FBBFA3E-3979-400D-83AE-55FCEEF4255D

P304

Q28193306-88296351-6E2F-4A9D-BC13-76566E3266AF

P31

Q28193306-CE2C0591-C0B9-4DF0-B7FF-8C464679EE7D

P3181

Q28193306-B1C24D86-3CF8-44A4-AD4B-CBDA2739696C

P356

Q28193306-597F035C-F988-4EA6-BA03-4228A75F4A68

P407

Q28193306-AF0C32F1-2F05-427C-8520-DA1D5AEDD207

P433

Q28193306-3FEA169A-538B-4A27-8A22-08B0CCDC6CB6

P478

Q28193306-CA88368D-8C3C-468C-9EAE-A6B773B90BFB

P50

Q28193306-1BC29870-AEDF-4766-97D4-92B1F1A119B3

Q28193306-9F757538-DDD7-434D-92D8-F6D1E306458E

Q28193306-A10AC72E-A7A9-4194-A858-D0B10AF4999B

P577

Q28193306-4A5F6C45-895E-4E71-97EA-B6BCB1AC8FE4

P5875

Q28193306-FA47AA8C-58DB-443B-9689-5069B8A527BF

P698

Q28193306-A198771F-24F3-4779-A9B4-530CCBD561AD

P921

Q28193306-4D429F3C-7030-4E66-842E-CB986DD222C6

P3181

P356

P1433

Journal of the American Medical Association

P1476

Cardiovascular disease outcome ...... ment Study follow-up (HERS II)

@en

P2093

Alan Herd

http://www.w3.org/2001/XMLSchema#string

David Herrington

http://www.w3.org/2001/XMLSchema#string

David Waters

http://www.w3.org/2001/XMLSchema#string

Deborah Grady

http://www.w3.org/2001/XMLSchema#string

Eric Vittinghoff

http://www.w3.org/2001/XMLSchema#string

HERS Research Group

http://www.w3.org/2001/XMLSchema#string

Judith Hsia

http://www.w3.org/2001/XMLSchema#string

Michael Davidson

http://www.w3.org/2001/XMLSchema#string

Nanette Wenger

http://www.w3.org/2001/XMLSchema#string

Roger Blumenthal

http://www.w3.org/2001/XMLSchema#string

P304

49-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

88384

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.288.1.49

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

288

http://www.w3.org/2001/XMLSchema#string

P50

L Kristin Newby

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236319222

http://www.w3.org/2001/XMLSchema#string

P698

12090862

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease